KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Receivables (2018 - 2025)

Castle Biosciences' Receivables history spans 7 years, with the latest figure at $43.4 million for Q4 2025.

  • For Q4 2025, Receivables fell 15.3% year-over-year to $43.4 million; the TTM value through Dec 2025 reached $43.4 million, down 15.3%, while the annual FY2025 figure was $43.4 million, 15.3% down from the prior year.
  • Receivables for Q4 2025 was $43.4 million at Castle Biosciences, down from $49.5 million in the prior quarter.
  • Across five years, Receivables topped out at $56.4 million in Q1 2025 and bottomed at $14.3 million in Q1 2021.
  • The 5-year median for Receivables is $34.2 million (2023), against an average of $34.1 million.
  • The largest annual shift saw Receivables surged 63.15% in 2023 before it decreased 15.3% in 2025.
  • A 5-year view of Receivables shows it stood at $17.3 million in 2021, then soared by 35.84% to $23.5 million in 2022, then surged by 63.15% to $38.3 million in 2023, then surged by 33.72% to $51.2 million in 2024, then dropped by 15.3% to $43.4 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Receivables are $43.4 million (Q4 2025), $49.5 million (Q3 2025), and $52.3 million (Q2 2025).